Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program

Diagnostic Microbiology and Infectious Disease

Volumn 56, Issue 3, 2006, Pages 341-344

  Turner, Philip J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Imipenem; Meropenem; Pseudomonas aeruginosa; Susceptibility

Indexed keywords

CARBAPENEM; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; IMIPENEM; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 33751039533     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.07.015     Document Type: Article

References (19)

1. Bouza E., Garrote-Garcia F., Cercenado E., Marin M., and Diaz M.S. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. Antimicrob. Agents Chemother. 43 (1999) 981-982
2. Chen H.Y., and Livermore D.M. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J. Antimicrob. Chemother. 35 (1994) 949-958
3. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 7th ed. (2006), CLSI, Wayne (PA) [Approved Standards M7-A7]
4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement M100-S16 (2006), CLSI, Wayne (PA)
5. Huang H., and Hancock R.E. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J. Bacteriol. 175 (1993) 7793-7800
6. Juan C., Gutierrez O., Oliver A., Ayestaran J.I., Borrell N., and Perez J.L. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infect. 11 (2005) 887-892
7. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right first time. Drugs 63 (2003) 2157-2168
8. Li X.Z., Zhang L., and Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45 (2000) 433-436
9. Livermore D.M. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47 (2001) 247-250
10. Perz F.J., Gimeno C., Navarro D., et al. Meropenem penetration through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. Chemotherapy 42 (1996) 210-214
11. VIM-4. J. Antimicrob. Chemother. 51 (2003) 1409-1414
12. Quinn J.P., Dudek E.J., DiVincenzo C.A., et al. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154 (1986) 289-294
13. Sinave C. Imipenem or meropenem, what is the best choice for Pseudomonas aeruginosa infections?. Med. Mal. Infect. 33 (2003) 579-583
14. Sofianou D., Tsakris A., Skoura L., and Douboyas J. Extended high-level cross resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital. J. Antimicrob. Chemother. 40 (1997) 740-742
15. Turner P.J. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J. Antimicrob. Chemother. 46 Suppl T2 (2000) 9-23
16. Turner P.J., Greenhalgh J.M., Edwards J.R., and McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme. Int. J. Antimicrob. Agents 13 (1999) 117-125
17. Unal S., and Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis. 53 (2005) 265-271
18. Villegas M.V., and Quinn J.P. An update on antibiotic-resistant gram-negative bacteria. Infect. Med. 21 (2004) 595-599
19. Walsh T.R., Toleman M.A., Poirel L., and Nordmann P. Metallo-beta-lactamases: the quiet before the storm?. Clin. Micro. Rev. 18 (2005) 306-325